CALA - Calithera Biosciences, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
6.80
+0.11 (+1.64%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close6.69
Open6.69
Bid6.70 x 900
Ask6.85 x 800
Day's Range6.60 - 6.91
52 Week Range2.45 - 7.64
Volume210,381
Avg. Volume606,752
Market Cap431.8M
Beta (5Y Monthly)2.49
PE Ratio (TTM)N/A
EPS (TTM)-2.03
Earnings DateNov 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.75
  • Is Calithera Biosciences, Inc.'s (NASDAQ:CALA) CEO Paid Enough Relative To Peers?
    Simply Wall St.

    Is Calithera Biosciences, Inc.'s (NASDAQ:CALA) CEO Paid Enough Relative To Peers?

    Susan Molineaux has been the CEO of Calithera Biosciences, Inc. (NASDAQ:CALA) since 2010. This report will, first...

  • GlobeNewswire

    Calithera Biosciences Provides Overview of 2020 Corporate Milestones and Financial Guidance

    Calithera Biosciences, Inc. (CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, provided today an overview of select expected fourth quarter 2019 financial results, initial 2020 financial guidance and upcoming corporate milestones. "We anticipate that 2020 will be an exciting year for Calithera, building on the substantial progress we made in 2019 and the potential for several significant clinical and regulatory milestones," said Susan Molineaux, PhD, president and chief executive officer of Calithera. Announce topline data from randomized CANTATA trial of telaglenastat with cabozantinib in advanced renal cell carcinoma (RCC).

  • GlobeNewswire

    Calithera Biosciences Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    Calithera Biosciences, Inc. (CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that the compensation committee of the company’s board of directors granted one new employee a non-qualified stock option to purchase an aggregate of 28,000 shares of Calithera’s common stock, at a per share exercise price of $5.71, the closing trading price on December 31, 2019. The stock option vests monthly over four years and was granted pursuant to the Calithera Biosciences, Inc. 2018 Inducement Plan, or Inducement Plan, which was approved by Calithera’s board of directors in January 2018 in accordance with Nasdaq Listing Rule 5635(c)(4).

  • Hedge Funds Are Dumping Calithera Biosciences Inc (CALA)
    Insider Monkey

    Hedge Funds Are Dumping Calithera Biosciences Inc (CALA)

    Before putting in our own effort and resources into finding a good investment, we can quickly utilize hedge fund expertise to give us a quick glimpse of whether that stock could make for a good addition to our portfolios. The odds are not exactly stacked in investors' favor when it comes to beating the market, […]

  • GlobeNewswire

    Data from Investigator-Sponsored Phase 2 Study of Calithera’s Telaglenastat with Azacitidine in Myelodysplastic Syndrome to be Presented at ASH Annual Meeting 2019

    Calithera Biosciences, Inc. (CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that preliminary safety and efficacy data from an investigator-sponsored trial evaluating telaglenastat (CB-839) in combination with azacitidine will be presented in an oral session at the American Society of Hematology (ASH) Annual Meeting 2019 taking place December 7-10, in Orlando, Florida.

  • GlobeNewswire

    Calithera Biosciences Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Calithera Biosciences, Inc. (CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that the compensation committee of the company’s board of directors granted four new employees non-qualified stock options to purchase an aggregate of 52,500 shares of Calithera’s common stock, at a per share exercise price of $4.92, the closing trading price on November 29, 2019. The stock options vest monthly over four years and were granted pursuant to the Calithera Biosciences, Inc. 2018 Inducement Plan, or Inducement Plan, which was approved by Calithera’s board of directors in January 2018 in accordance with Nasdaq Listing Rule 5653(c)(4).

  • Thomson Reuters StreetEvents

    Edited Transcript of CALA earnings conference call or presentation 12-Nov-19 10:00pm GMT

    Q3 2019 Calithera Biosciences Inc Earnings Call

  • Imagine Owning Calithera Biosciences (NASDAQ:CALA) While The Price Tanked 64%
    Simply Wall St.

    Imagine Owning Calithera Biosciences (NASDAQ:CALA) While The Price Tanked 64%

    Over the last month the Calithera Biosciences, Inc. (NASDAQ:CALA) has been much stronger than before, rebounding by...

  • GlobeNewswire

    Calithera Biosciences Reports Third Quarter 2019 Financial Results and Recent Highlights

    SOUTH SAN FRANCISCO, Calif., Nov. 12, 2019 -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel.

  • GlobeNewswire

    Calithera to Present Preclinical Data from IL4I1 and CD73 Programs at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

    Calithera Biosciences, Inc. (CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that new data from its research and development portfolio have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting taking place November 6-10, 2019, in National Harbor, Maryland. “We look forward to sharing the first data on IL4I1, which is an investigational first-in-class small molecule immune-oncology program, as well as new data from the development program for our novel CD73 inhibitor CB-708,” said Susan Molineaux, PhD, president and chief executive officer of Calithera.

  • GlobeNewswire

    Calithera Biosciences to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019

    Calithera Biosciences, Inc. (CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that the Company’s third quarter 2019 financial results will be released on Tuesday, November 12, 2019. Company management will host a conference call on Tuesday, November 12, 2019 at 2:00 p.m. Pacific Time/ 5:00 p.m. Eastern Time to discuss the financial results and other recent corporate highlights. The press release and live audio webcast can be accessed via the Investor section of the Company’s website at www.calithera.com.

  • Read This Before Selling Calithera Biosciences, Inc. (NASDAQ:CALA) Shares
    Simply Wall St.

    Read This Before Selling Calithera Biosciences, Inc. (NASDAQ:CALA) Shares

    We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...

  • American City Business Journals

    These 24 Bay Area drug and diagnostics companies quietly raised nearly $3B this year

    While initial public offerings get most of the splash, public companies also are raking in cash with follow-on offerings. How long will the Wall Street spigot stay open?

  • Calithera (CALA) Completes Enrollment in Mid-Stage RCC Study
    Zacks

    Calithera (CALA) Completes Enrollment in Mid-Stage RCC Study

    Calithera (CALA) completes patient enrollment in a phase II study evaluating a combination regimen of its lead candidate, telaglenastat, in patients with advanced kidney cancer.

  • GlobeNewswire

    Calithera Biosciences Completes Patient Enrollment in Randomized CANTATA Trial of Telaglenastat and Cabozantinib in Advanced Renal Cell Carcinoma

    Calithera Biosciences, Inc. (CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that it has completed patient enrollment in the ongoing CANTATA trial. CANTATA is a global, randomized double-blind clinical trial of the glutaminase inhibitor telaglenastat (CB-839) combined with cabozantinib, a standard of care, in patients with advanced or metastatic renal cell carcinoma (RCC) who have received one or two prior treatments. Exelixis, Inc. is providing cabozantinib for the trial through a material supply agreement with Calithera.

  • GlobeNewswire

    Calithera Announces Acceptance of Two Abstracts for Presentation at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting

    Calithera Biosciences, Inc. (CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that new data from its research and development portfolio will be featured in two poster presentations at the upcoming Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting 2019 in National Harbor, Maryland, taking place November 6-10. “The preclinical IL4I1 immuno-oncology program is an exciting new addition to our pipeline, and we are pleased that initial data from this program, as well as our ongoing CB-708 preclinical program, have been accepted for presentation at this high-profile meeting,” said Susan Molineaux, PhD, president and chief executive officer of Calithera.

  • GlobeNewswire

    New Data Presented at ESMO Congress 2019 from the Arginase Inhibitor INCB001158 Alone and in Combination with Pembrolizumab

    Calithera Biosciences, Inc. (CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced the presentation of new data from the investigational first-in-class oral arginase inhibitor INCB001158 as a monotherapy and in combination with the checkpoint inhibitor pembrolizumab in microsatellite stable (MSS) colorectal carcinoma patients. The data were presented during an oral Proffered Paper session at the European Society for Medical Oncology (ESMO) Congress 2019 taking place in Barcelona, Spain (Abstract #440O).

  • GlobeNewswire

    Data From Randomized Phase 2 ENTRATA Study Demonstrate Telaglenastat with Everolimus Improves Progression-Free Survival in Renal Cell Carcinoma

    Calithera Biosciences, Inc. (CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, presented today supporting data for its previously reported positive results from its randomized placebo-controlled Phase 2 ENTRATA study of telaglenastat (CB-839) in combination with everolimus in patients with advanced renal cell carcinoma (RCC). The telaglenastat-everolimus combination doubled the median progression-free survival (PFS) in heavily pre-treated patients with advanced RCC and had a well-tolerated safety profile.

  • Calithera Biosciences Enters Oversold Territory
    Zacks

    Calithera Biosciences Enters Oversold Territory

    Calithera Biosciences has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

  • GlobeNewswire

    Calithera to Host Webcast Conference Call for Analysts and Investors During European Society for Medical Oncology (ESMO) Congress 2019

    SOUTH SAN FRANCISCO, Calif., Sept. 26, 2019 -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel.

  • Implied Volatility Surging for Calithera (CALA) Stock Options
    Zacks

    Implied Volatility Surging for Calithera (CALA) Stock Options

    Investors need to pay close attention to Calithera (CALA) stock based on the movements in the options market lately.

  • GlobeNewswire

    Calithera to Present at the 2019 Cantor Global Healthcare Conference

    Calithera Biosciences, Inc. (CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that Susan M. Molineaux, Ph.D, the company’s founder, president and chief executive officer, will present at the 2019 Cantor Global Healthcare Conference at 1:45 p.m. ET on Friday, October 4, 2019 in New York. Calithera Biosciences is a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted therapies that disrupt cellular metabolic pathways to preferentially block tumor cells and enhance immune-cell activity. Driven by a commitment to rigorous science and a passion for improving the lives of people impacted by cancer and other life-threatening diseases, Calithera is advancing a pipeline of first-in-clinic, oral therapeutics to meaningfully expand treatment options available to patients.

  • Calithera Biosciences, Inc. (NASDAQ:CALA): Is It Growing Too Fast?
    Simply Wall St.

    Calithera Biosciences, Inc. (NASDAQ:CALA): Is It Growing Too Fast?

    As the US$213m market cap Calithera Biosciences, Inc. (NASDAQ:CALA) released another year of negative earnings...

  • Thomson Reuters StreetEvents

    Edited Transcript of CALA earnings conference call or presentation 8-Aug-19 9:00pm GMT

    Q2 2019 Calithera Biosciences Inc Earnings Call

  • GlobeNewswire

    Calithera to Participate in Wells Fargo Healthcare Conference and Citi 14th Annual Biotech Conference

    Calithera Biosciences, Inc. (CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced its participation at two upcoming healthcare investor conferences in September. Susan M. Molineaux, Ph.D., the company’s founder, president and chief executive officer, will present in Boston on Wednesday, September 4, 2019, at 1:50 p.m. Eastern Time. Calithera Biosciences is a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted therapies that disrupt cellular metabolic pathways to preferentially block tumor cells and enhance immune-cell activity.